Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Radiographic progression-free survival correlation with time-to-event endpoints: A post hoc analysis of the VISION trial
    Meeting Abstract

    Morris, M. J.; de Bono, J. S.; Nagarajah, J.; Wei, X. X.; Nordquist, L. T.; Koshkin, V. S.; Vickers, A.; Mirante, O.; Ghouse, R.; Tagawa, S. T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Xie, W.; Carducci, M. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial
    Meeting Abstract

    Nicolle, R.; Bachet, J. B.; Harlé, A.; Iovanna, J. L.; Hammel, P.; Rebours, V.; Turpin, A.; Ben Abdelghani, M.; Wei, A.; Mitry, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Meeting Abstract

    Keane, F.; Park, W.; Varghese, A.; Balogun, F.; Yu, K.; El Dika, I.; Khalil, D.; Kelsen, D. P.; Reidy-Lagunes, D.; Ku, G. Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI
    Meeting Abstract

    Mok, T. S. K.; Wu, Y. L.; Nishio, M.; Reck, M.; Wu, E.; Sternberg, D. W.; Esker, S.; Yu, H. A.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Meeting Abstract

    Ku, G. Y.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in
    Meeting Abstract

    Shitara, K.; Ben-Aharon, I.; Rojas, C.; Eyzaguirre, D. A. A.; Hubert, A.; Moya, H. A.; Cohen, D.; Bai, L. Y.; Ghiringhelli, F.; Wyrwicz, L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Yu, H. A.; Cantero, F.; Kim, B.; Lee, M.; Wu, E.; Sternberg, D. W.; Jänne, P. A.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save